<label id="xi47v"><meter id="xi47v"></meter></label>

      Higher doses of radiation don't improve survival in prostate cancer: study

      Source: Xinhua| 2018-03-16 06:07:14|Editor: yan
      Video PlayerClose

      CHICAGO, March 15 (Xinhua) -- Compared with standard radiation treatment, higher doses of radiation do not improve survival for many patients with prostate cancer, a study led by researchers at Washington University School of Medicine in St. Louis shows.

      The study included about 1,500 patients with intermediate-risk prostate cancer that most patients fall into. To be classified in this risk category, patients generally have PSA scores of 10-20 ng/ml and a Gleason score of seven.

      Both treatment groups received external beam radiation. The standard group received a radiation dose of 70.2 gray delivered over 39 treatment visits. The investigational group received increasing doses up to 79.2 gray delivered over 44 visits. A gray is the standard measure of radiation a material has absorbed.

      Of the 748 men receiving standard treatment, 75 percent were still alive after eight years of follow-up. Of the 751 men receiving the dose-escalation treatment, 76 percent were alive at the eight-year mark, a difference that is not statistically significant.

      Over the course of the study, 51 patients died of prostate cancer, which is 3.4 percent of all patients enrolled. At the eight-year mark, the death rate due to prostate cancer for patients receiving standard treatment was four percent compared with two percent for patients receiving the escalating dose. These rates also were not statistically different.

      While there was no difference in overall survival numbers, Jeff M. Michalski, first author and professor of radiation oncology of Washington University, pointed out some differences in side effects and in whether further treatment was needed later.

      Patients in the standard dose group were more likely to undergo further therapies to control tumors that had grown larger or that had spread to another site in the body. While patients in the escalating dose group experienced more side effects, such as urinary irritation or rectal bleeding, sometimes years after treatment.

      During the 10 years it took to enroll enough patients in the trial, at least six new therapies were approved for recurrent or metastatic prostate cancer, and these therapies have been shown to improve survival.

      "If there is a difference between standard and escalating doses, it's hard to show it when the patients who later develop recurrent cancer can have their lives extended through the use of additional therapies," said Michalski.

      The study, the first that is large enough to examine whether these improved measurements translate into longer survival for patients, is published Thursday in JAMA Oncology.

      TOP STORIES
      EDITOR’S CHOICE
      MOST VIEWED
      EXPLORE XINHUANET
      010020070750000000000000011105521370422301
      主站蜘蛛池模板: 一本天堂ⅴ无码亚洲道久久| 国产成人精品久久亚洲高清不卡 | 人人揉揉香蕉大免费不卡| 免费一看一级毛片全播放| 综合偷自拍亚洲乱中文字幕| 成人免费看吃奶视频网站| 亚洲香蕉久久一区二区三区四区| 日本免费人成在线网站| 亚洲系列国产精品制服丝袜第| 222www在线观看免费| 亚洲人成电影青青在线播放| 很黄很黄的网站免费的| 国产成人亚洲综合一区| 国产免费牲交视频| 日本视频免费观看| 国产亚洲一区二区在线观看| 久久青草免费91线频观看不卡| 亚洲综合一区二区精品久久| 免费在线看v网址| 亚洲精品无码专区| 亚洲精品A在线观看| 中国一级特黄高清免费的大片中国一级黄色片| 自拍偷自拍亚洲精品情侣| 人人玩人人添人人澡免费| 亚洲免费观看网站| 韩国欧洲一级毛片免费| 国产成人1024精品免费| 久久精品国产亚洲AV无码麻豆| 欧洲乱码伦视频免费| 深夜免费在线视频| 亚洲国产精品国自产拍电影| 最近中文字幕mv手机免费高清| 美女羞羞视频免费网站| 亚洲国产成人片在线观看 | 亚洲熟妇自偷自拍另欧美| 免费萌白酱国产一区二区| 中文在线免费不卡视频| 亚洲av永久无码精品三区在线4 | 亚洲综合无码一区二区三区| 日本不卡高清中文字幕免费| 99久久婷婷免费国产综合精品|